Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, for its balance sheet. This decision follows the coin's recent all-time high price of $808. The company aims to raise $520 million through a combination of a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp. Windtree is partnering with crypto exchange Kraken for asset custody. BNB, which has a market cap of $106.9 billion, was trading at $769 when announced. This move aligns with a broader trend of publicly traded companies, including firms like Nano Labs that have purchased crypto assets to enhance their financial standing. Windtree's stock has seen significant fluctuations, increasing by 162% over the last month despite a recent 5% decline.

Source 🔗